These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28535776)

  • 1. The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan.
    Chen T; Chan S; Lack G; Cro S; Cornelius VR
    Trials; 2017 May; 18(1):231. PubMed ID: 28535776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial.
    Chan S; Cornelius V; Chen T; Radulovic S; Wan M; Jahan R; Lack G
    Trials; 2017 Mar; 18(1):136. PubMed ID: 28330497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.
    Chan S; Cornelius V; Cro S; Harper JI; Lack G
    JAMA Pediatr; 2020 Jan; 174(1):29-37. PubMed ID: 31764962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.
    Iyengar SR; Hoyte EG; Loza A; Bonaccorso S; Chiang D; Umetsu DT; Nadeau KC
    Int Arch Allergy Immunol; 2013; 162(1):89-93. PubMed ID: 23816920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.
    Andorf S; Purington N; Block WM; Long AJ; Tupa D; Brittain E; Rudman Spergel A; Desai M; Galli SJ; Nadeau KC; Chinthrajah RS
    Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):85-94. PubMed ID: 29242014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese herbal medicine granules (PTQX) for children with moderate to severe atopic eczema: study protocol for a randomised controlled trial.
    Gu SX; Zhang AL; Coyle ME; Mo X; Lenon GB; Cranswick NE; Chen D; Xue CC
    Trials; 2015 Jul; 16():294. PubMed ID: 26149448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab.
    Zink A; Gensbaur A; Zirbs M; Seifert F; Suarez IL; Mourantchanian V; Weidinger S; Mempel M; Ring J; Ollert M
    Acta Derm Venereol; 2016 Jan; 96(1):72-6. PubMed ID: 26059424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of omalizumab in paediatric age: an update of literature data.
    Matin N; Tabatabaie O; Falsaperla R; Pavone P; Serra A; Cocuzza S; Di Mauro P; Licciardello L; Lubrano R; Vitaliti G
    J Biol Regul Homeost Agents; 2016; 30(2):579-84. PubMed ID: 27358151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis.
    Bangert C; Loesche C; Skvara H; Fölster-Holst R; Lacour JP; Jones J; Burnett P; Novak N; Stingl G
    J Invest Dermatol; 2023 Oct; 143(10):1896-1905.e8. PubMed ID: 37004878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit].
    Schmitt J; Schäkel K
    Hautarzt; 2007 Feb; 58(2):128, 130-2. PubMed ID: 17237929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab treatment in severe adult atopic dermatitis.
    Thaiwat S; Sangasapaviliya A
    Asian Pac J Allergy Immunol; 2011 Dec; 29(4):357-60. PubMed ID: 22299316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermatologic uses of omalizumabtitle.
    Chia JC; Mydlarski PR
    J Dermatolog Treat; 2017 Jun; 28(4):332-337. PubMed ID: 27759482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study.
    Heil PM; Maurer D; Klein B; Hultsch T; Stingl G
    J Dtsch Dermatol Ges; 2010 Dec; 8(12):990-8. PubMed ID: 20678148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis.
    Amrol D
    South Med J; 2010 Jun; 103(6):554-8. PubMed ID: 20710140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab.
    Zengarini C; Roda M; Schiavi C; Bruni F; Bardazzi F; Bellusci C; Raone B
    Clin Exp Dermatol; 2022 Mar; 47(3):604-606. PubMed ID: 34731495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.
    Sheinkopf LE; Rafi AW; Do LT; Katz RM; Klaustermeyer WB
    Allergy Asthma Proc; 2008; 29(5):530-7. PubMed ID: 18926061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A serie of cases.
    García M; Durán-Crane A; Chapman E; García E
    Rev Alerg Mex; 2019; 66(3):282-291. PubMed ID: 31606011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab for atopic dermatitis: case series and a systematic review of the literature.
    Holm JG; Agner T; Sand C; Thomsen SF
    Int J Dermatol; 2017 Jan; 56(1):18-26. PubMed ID: 27337170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of omalizumab efficacy in severe atopic dermatitis with extremely elevated IgE levels: two case reports and a literature review.
    Nečas M; Vašků V; Březinová E
    Acta Dermatovenerol Alp Pannonica Adriat; 2019 Jun; 28(2):89-92. PubMed ID: 31233174
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.